Nuvation Bio's (NUVB) "Outperform" Rating Reaffirmed at Royal Bank Of Canada

Key Points

• Royal Bank of Canada reaffirmed an "Outperform" rating with a $20 price objective, implying a potential upside of about 319.73% from the stock's prior close.
• Nuvation reported Q1 revenue of $83.2M (above consensus) and $18.5M in net product revenues for IBTROZI, with EPS of $0.01, but the company still posts deep historical losses (net margin -325.31% and negative ROE).
• Analyst coverage is mixed but tilted positive: eight Buys, one Hold and one Sell, giving a consensus rating of "Moderate Buy" and an average price target of $12.50.

Nuvation Bio (NYSE:NUVB - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at Royal Bank Of Canada in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. Royal Bank Of Canada's price objective points to a potential upside of 319.73% from the stock's previous close.

NUVB has been the topic of a number of other reports. UBS Group dropped their price objective on shares of Nuvation Bio from $10.00 to $7.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvation Bio in a research report on Tuesday, April 21st. HC Wainwright reissued a "buy" rating and set a $17.00 price target on shares of Nuvation Bio in a research report on Tuesday. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Nuvation Bio in a research report on Tuesday. Finally, Truist Financial set a $13.00 price target on shares of Nuvation Bio in a research report on Tuesday, January 27th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $12.50.

Nuvation Bio Stock Up 8.0%

Shares of Nuvation Bio stock traded up $0.36 during trading hours on Tuesday, reaching $4.77. The company's stock had a trading volume of 6,565,769 shares, compared to its average volume of 4,891,869. Nuvation Bio has a one year low of $1.57 and a one year high of $9.75. The company has a market capitalization of $1.66 billion, a P/E ratio of -7.98 and a beta of 1.51. The stock's fifty day simple moving average is $4.72 and its two-hundred day simple moving average is $5.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The firm had revenue of $83.23 million for the quarter, compared to analyst estimates of $65.73 million. On average, research analysts forecast that Nuvation Bio will post -0.47 earnings per share for the current year.

Insider Activity

In other Nuvation Bio news, insider Dongfang Liu sold 50,000 shares of Nuvation Bio stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $5.02, for a total value of $251,000.00. Following the sale, the insider owned 18,000 shares of the company's stock, valued at approximately $90,360. The trade was a 73.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 36,750 shares of Nuvation Bio stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.01, for a total transaction of $184,117.50. Following the completion of the sale, the insider directly owned 53,000 shares in the company, valued at approximately $265,530. This represents a 40.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 286,750 shares of company stock worth $1,339,118. Insiders own 30.11% of the company's stock.

Institutional Trading of Nuvation Bio

Hedge funds have recently added to or reduced their stakes in the stock. Rangeley Capital LLC bought a new stake in Nuvation Bio in the second quarter worth about $25,000. Parallel Advisors LLC increased its stake in shares of Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company's stock worth $28,000 after purchasing an additional 2,597 shares in the last quarter. Cetera Investment Advisers purchased a new position in shares of Nuvation Bio in the second quarter worth about $29,000. Captrust Financial Advisors purchased a new position in shares of Nuvation Bio in the second quarter worth about $32,000. Finally, Swiss Life Asset Management Ltd purchased a new position in shares of Nuvation Bio in the third quarter worth about $39,000. Institutional investors own 61.67% of the company's stock.

Trending Headlines about Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Wedbush reaffirmed an "outperform" rating and set an $11.00 price target — signaling sizable upside from current levels and likely supporting buying interest. Benzinga
• Positive Sentiment: HC Wainwright reaffirmed a "buy" rating and raised its price target to $17.00, which is a bullish endorsement that may attract growth-oriented investors. Benzinga
• Positive Sentiment: Company Q1 results showed revenue of $83.2M (above consensus) and reported net product revenues of $18.5M for IBTROZI, with management highlighting launch momentum and adoption in first-line ROS1+ NSCLC — these operational signs and a cash balance of ~$533.7M underpin near-term execution and funding. PR Newswire
• Neutral Sentiment: Q1 2026 earnings call transcript is available for investors who want detail on guidance, commercialization cadence and pipeline development — useful for assessing sustainability of the revenue beat and management commentary. Earnings Call Transcript
• Negative Sentiment: Zacks reported that Nuvation missed its Q1 EPS estimate (reported $0.01 vs. Zacks’ $0.12), which could temper enthusiasm among earnings-focused traders and explains some of the mixed market reactions. Zacks
• Negative Sentiment: Despite the revenue beat, the company still shows deep historical losses (large negative net margin and negative ROE), which keeps valuation and profitability questions in play for longer-term investors. MarketBeat

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.